Quinolizin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: Quinolizin-2-one
• 化学式: C₉H₇NO
• mdl: MFCD00234515
• 分子量: 145.16
• InChiKey: DGCWHOHVNONFSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES DIHYDROQUINOLIZINONES POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015173164A1

  公开（公告）日：2015-11-19

  The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X and Y are as described in the description and in the claims, as well as or pharmaceutically acceptable salts, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.

  该发明提供了具有以下一般式的新化合物：其中R1、R2、R3、R4、R5、R6、X和Y如描述和权利要求中所述，以及其药学上可接受的盐，或对映体，或非对映异构体。该发明还包括包括这些化合物的组合物和使用这些化合物的方法。
• [EN] NOVEL 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVEAUX DÉRIVÉS DE 6,7-DIHYDROBENZO[A]QUINOLIZIN-2-ONE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016071215A1

  公开（公告）日：2016-05-12

  The invention provides novel compounds having the general formula (I) wherein R1 to R6, W and X are as described herein and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般式（I）的新化合物，其中R1至R6、W和X如本文所述，以及它们的药用盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• [EN] ANTIMICROBIAL 4-OXOQUINOLIZINES<br/>[FR] 4-OXOQUINOLIZINES ANTIMICROBIENNES
  申请人：EVOLVA SA

  公开号：WO2012104305A1

  公开（公告）日：2012-08-09

  This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

  这项发明提供了新颖的4-氧喹啉化合物及其用途，用于一系列广谱抗生素，不会产生对现有或新出现的抗生素类别的交叉耐药性。此外，这些新颖的4-氧喹啉化合物对CDC A类和B类病原体具有作用。该发明还提供了包含某些4-氧喹啉与亚抑菌浓度的多粘菌素B结合的药物组合物，用于对抗对喹诺酮、碳青霉烯和其他抗微生物药物产生耐药性的临床分离株。
• [EN] A NOVEL PROCESS FOR PREPARATION OF DEUTETRABENAZINE<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE DEUTÉTRABÉNAZINE
  申请人：ALAPARTHI LAKSHMI PRASAD

  公开号：WO2019150387A1

  公开（公告）日：2019-08-08

  A novel process for preparation of Deutetrabenazine ((RR, SS)-l,3,4,6,7-llb-Hexahydro-9,10-di(methoxy-d6)-3-(2-methylpropyl)-2H- benzo [a] quinolizin-2-one) of formula I comprises of methylation of N-(2-(3,4-dihydroxy-phenyl)-ethyl)-formamide compound of formula III with deuteriated methanol (CD3OD or CD3OH) to obtain d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide compound of formula IV; cyclization of d6-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-formamide in presences of dehydrating agent to obtain d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V; reacting d6-6,7-Dimethoxy-3,4-dihydroisoquinoline compound of formula V with 2-acetyl-N,N,N,4-tetramethyl-1-pentanaminium iodide compound of formula VI.

  一种用于制备Deutetrabenazine ((RR, SS)-l,3,4,6,7-llb-六氢-9,10-二(甲氧基-d6)-3-(2-甲基丙基)-2H-苯并[a]喹啉-2-酮)的新型工艺包括将式III的N-(2-(3,4-二羟基苯基)-乙基)-甲酰胺化合物与氘化甲醇(CD3OD或CD3OH)甲基化，得到式IV的d6-N-(2-(3,4-二甲氧基苯基)-乙基)-甲酰胺化合物；在脱水剂存在下将d6-N-(2-(3,4-二甲氧基苯基)-乙基)-甲酰胺环化，得到式V的d6-6,7-二甲氧基-3,4-二氢异喹啉化合物；将式V的d6-6,7-二甲氧基-3,4-二氢异喹啉化合物与式VI的2-乙酰-N,N,N,4-四甲基-1-戊胺碘化物发生反应。
• [EN] METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS<br/>[FR] PROCÉDÉS DE PRODUCTION DE COMPOSÉS DE BENZOQUINOLINE
  申请人：AUSPEX PHARMACEUTICALS INC

  公开号：WO2015084622A1

  公开（公告）日：2015-06-11

  The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof. Novel methods of manufacturing benzoquinoline compounds of formula (I), including tetrabenazine and deuterated tetrabenazine analogs such as d6-tetrabenazine are disclosed herein. Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor and is commonly prescribed for the treatment of Huntington's disease. d6-Tetrabenazine is a deuterated analog of tetrabenazine which has improved pharmacokinetic properties when compared to the non-deuterated drug and is currently under clinical development.

  本发明涉及制造新的制造囊泡单胺转运体2（VMAT2）苯醌啉抑制剂的方法及其中间体。本文披露了制造公式（I）的苯醌啉化合物的新方法，包括四苯异卓和氘代四苯异卓类似物，如d6-四苯异卓。四苯异卓是一种VMAT2抑制剂，通常用于治疗亨廷顿病。d6-四苯异卓是四苯异卓的氘代类似物，与非氘代药物相比，具有改善的药代动力学性能，并目前正在进行临床开发。